Plasma Donors hold the missing puzzle piece for those who rely on plasma-derived therapies.
October is Plasma Awareness Month, an opportunity for CSL to raise awareness about the importance and need for plasma donations to manufacture life-saving therapies.Continue reading
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price
THOUSAND OAKS, Calif. Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.Continue reading
[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.Continue reading
The ABRC relies on subject matter experts (SMEs) from around the globe to evaluate the merits of grant applications received. Research Grant Peer Reviewers review each application in accordance with guidelines provided by ABRC and provide a written review and scores to ABRC.Continue reading
The Arizona Legislature appropriated up to $5,000,000 beginning in fiscal year 2025-2026 to fund phase one (1), two (2), and/or three (3) clinical trials. This funding will run for five (5) years from the date of award and is exempt from lapsing.Continue reading
Jennifer Barton, PhD, is spearheading an effort to diagnose ovarian cancer earlier and give high-risk patients a new option.Continue reading
WASHINGTON, D.C. – AdvaMed, the Medtech Association, recently published a technical performance and safety bulletin titled, “Remote Device Operations: Common Challenges and Mitigation Strategies” to help health care providers, device manufacturers, and IT teams navigate the complex landscape of remotely managing medical devices.Continue reading
The new systems represent a leap in non-invasive imaging. The machines, powered by artificial intelligence, open new possibilities for treating neurological diseases such as Alzheimer’s and Parkinson’s, as well as expanding the capabilities for imaging the heart, lungs and liver – even for patients with metallic implants.
TUCSON, Ariz., Sept. 30, 2025 — Critical Path Institute® (C-Path) today announced the election of Colin Hill, M.S., to its Board of Directors. Hill brings deep experience at the intersection of artificial intelligence, drug development, and translational acceleration. The appointment will further strengthen C-Path’s Board of Directors’ commitment to provide optimal strategic support to the organization’s growth in advancing drug development through collaboration.Continue reading